Neuropsychological evaluations help patients with neurofibromatosis manage cognitive and behavioral challenges affecting their daily lives [1].

These evaluations are critical because neurofibromatosis often involves more than physical symptoms. By addressing learning, memory, and mood issues, clinicians can improve the overall quality of life for patients and their families.

During the Neurofibromatosis Symposium in 2024, neuropsychologist Dr. Pamela Dean detailed the role of the Cleveland Clinic's neuropsychology program [1]. The program focuses on identifying the specific cognitive and behavioral hurdles that frequently accompany neurofibromatosis and schwannomatosis [1].

According to the presentation, these conditions often lead to difficulties with attention and memory [1]. Neuropsychological evaluations allow specialists to map these challenges and develop tailored management strategies to help patients navigate school and work environments.

Dr. Dean said the goal of these evaluations is to provide families with a better understanding of how to manage the condition [1]. This approach focuses on the intersection of brain function and behavior, addressing how the disorder impacts mood and social interaction.

The symposium served as a platform to emphasize that cognitive support is a necessary component of comprehensive care [1]. By integrating neuropsychology into the treatment plan, the Cleveland Clinic aims to reduce the frustration and isolation often felt by those with these genetic conditions.

Management strategies include interventions for attention deficits and learning disabilities [1]. These tools are designed to support the patient's autonomy and improve their ability to function in daily life.

Neuropsychological evaluations help patients with neurofibromatosis manage cognitive and behavioral challenges.

The emphasis on neuropsychological evaluation marks a shift toward holistic care for neurofibromatosis. By treating cognitive and behavioral symptoms as core components of the disease rather than secondary side effects, medical institutions can provide more effective, personalized support for patients facing lifelong genetic challenges.